BioWorld

June 27, 2007

Genentech, Abbott Partner To Develop Oncology Drugs

Genentech Inc. is acting the pharma part in a deal with Abbott to advance the latter's Phase I-stage compounds ABT-263 and ABT-869, a Bcl-2 protein antagonist and VEGF receptor kinase inhibitor, respectively. (BioWorld Today) Read More

MediciNova Picks 2 Programs, Looks To Partner Most Others

Broader Comparison Finds More Specific Angiogenesis Markers

NewCo News: Cequent's RNAi Platform Draws Novartis Investment, Option

Generex Gears Up For Phase III Trial Of Oral-lyn Insulin Spray

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Feb. 2, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...

Illustration of brain with neuron receptor

5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

BioWorld Science

Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...